Insulin Glulisine, a New Rapid-Acting Insulin Analogue, Displays a Rapid Time-Action Profile in Obese Non-Diabetic Subjects

Abstract

Aims/hypothesis: This study compared the pharmacokinetics and pharmacodynamics of insulin glulisine, insulin lispro, and regular human insulin in obese subjects. Methods: In this single-dose, randomized, double-blind, crossover euglycaemic clamp study, 18 non-diabetic subjects (mean body mass index [BMI] 34.7 kg · m^-2) were randomized to receive subcutaneous injections of each insulin (0.3 U · kg^-1) in pre-determined sequences. Results: Insulin glulisine and insulin lispro had more rapid-acting profiles than regular human insulin. Fractional glucose infusion rate (GIR)-area under curves (AUC) of the GIR curve and maximum GIR were greater for insulin glulisine and insulin lispro versus regular human insulin. Total glucose disposal was slightly greater with insulin glulisine than with regular human insulin, and was comparable to insulin lispro, although it decreased with increasing insulin resistance (HOMA index) with all insulins. Time to 20 % (early glucose disposal) and 80 % (bulk of activity) of total GIR-AUC were shorter for insulin glulisine and insulin lispro versus regular human insulin. This was corroborated by more rapid and shorter residing pharmacokinetic profiles of insulin glulisine and insulin lispro versus regular human insulin, evidenced by shorter times to 20 % of total INS-AUC, INS-C_max (INS-t_max), and mean residence time. Moreover, time to 20 % of total GIR-AUC demonstrated a less rapid-acting profile for insulin lispro versus insulin glulisine, which was consistent with the slightly less rapid pharmacokinetic profile of insulin lispro. There was no significant correlation between BMI or subcutaneous fat thickness and pharmacokinetic or pharmacodynamic profiles for insulin glulisine, unlike insulin lispro and regular human insulin. Conclusions/interpretation: Insulin glulisine and insulin lispro demonstrated substantially more rapid time-action profiles than regular human insulin in obese non-diabetic subjects, which prevailed with insulin glulisine irrespective of BMI and subcutaneous fat thickness.

Obesity - insulin analogues - pharmacokinetics - pharmacodynamics

References

• 1 Bakaysa D L, Radziuk J, Havel H A, Brader M L, Li S, Dodd S W, Beals J M, Pekar A H, Brems D N. Physicochemical basis for the rapid time-action of Lys B28 ProB29-insulin: Dissociation of a protein ligand complex.  Protein Science. 1996;  5 2521-2531
• 2 Becker R, Frick A, Wessels D, Scholtz H. Evaluation of the pharmacodynamic and pharmacokinetic profiles of insulin glulisine - a novel, rapid-acting, human insulin analogue.  Diabetologia. 2003;  46 A775 (Abstract)
• 3 Clauson P G, Linde B. Absorption of rapid-acting insulin in obese and nonobese NIDDM patients.  Diabetes Care. 1995;  18 986-991
• 4 DECODE Study Group . Glucose tolerance and cardiovascular mortality: comparison of fasting and 2-hour diagnostic criteria.  Arch Intern Med. 2001;  161 397-405
• 5 Diabetes Control and Complications Trial Research Group . The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus.  N Engl J Med. 1993;  329 (14) 977-986
• 6 Frick A, Becker R, Wessels D, Scholtz H. Pharmacokinetic and glucodynamic profiles of insulin glulisine: an evaluation following subcutaneous administration at various injection sites.  Diabetologia. 2003;  46 A776 (Abstract)
• 7 Gautier J F, Mourier A, de Kerviler E, Tarentola A, Bigard A X, Villette J M, Guezennec C Y, Cathelineau G. Evaluation of abdominal fat distribution in noninsulin-dependent diabetes mellitus: relationship to insulin resistance.  J Clin Endocrinol Metab. 1998;  83 1306-1311
• 8 Hayes P A, Sowood P J, Belyavin A, Cohen J B, Smith F W. Sub-cutaneous fat thickness measured by magnetic resonance imaging, ultrasound, and calipers.  Med Sci Sports Exerc. 1998;  20 303-309
• 9 Heinemann L, Weyer C, Rauhaus M, Heinrichs S, Heise T. Variability of the metabolic effect of soluble insulin and the rapid-acting insulin analogue insulin aspart.  Diabetes Care. 1998;  21 1910-1914
• 10 Heise T, Nosek L, Spitzer H, Heinemann L. Glulisine. Schnellerer Wirkbeginn als Lispro bei schlanken bis stark übergewichtigen Patienten.  Diabetes und Stoffwechsel. 2005;  14 P-20
• 11 Hennige A M, Lehmann R, Weigert C, Moeschel K, Schäuble M, Metzinger E, Lammers R, Häring H U. Insulin Receptor Signaling Characteristics In Vivo.  Diabetes. 2005;  54 361-366
• 12 Home P D, Barriocanal L, Lindholm A. Comparative pharmacokinetics and pharmacodynamics of the novel rapid-acting insulin analogue, insulin aspart, in healthy volunteers.  Eur J Clin Pharmacol. 1999;  55 199-203
• 13 Howey D C, Bowsher R R, Brunelle R L, Woodworth J R. [Lys(B28), Pro (B29)]-Human insulin. A rapidly absorbed analogue of human insulin.  Diabetes. 1994;  43 396-402
• 14 Kroon K. Chapter 13: Insulin - pharmacology, types of regimens and adjustments. http://www.endotext.com October.26.2003
• 15 Matthews D R, Hosker J P, Rudenski A S, Naylor B A, Treacher D F, Turner R C. Homeostasis model assessment: insulin resistance and β-cell function from fasting plasma glucose and insulin concentrations in man.  Diabetologia. 1985;  28 412-419
• 16 Pfeifer M A, Halter J B, Porte Jr D. Insulin secretion in diabetes mellitus.  Am J Med. 1981;  70 579-588
• 17 Ponchner M, Heine R J, Pernet A, Hanning I, Francis A J, Cook D, Orskov H, Alberti K G. A comparison of the artificial pancreas (glucose controlled insulin infusion system) and a manual technique for assessing insulin sensitivity during euglycaemic clamping.  Diabetologia. 1984;  26 420-425
• 18 Rakatzi I, Ramrath S, Ledwig D, Dransfeld O, Bartels T, Seipke G, Eckel J. A novel insulin analogue with unique properties: LysB3, GluB29 insulin induces prominent activation of insulin receptor substrate 2, but marginal phosphorylation of insulin receptor substrate 1.  Diabetes. 2003;  52 2227-2238
• 19 Sindelka G, Heinemann L, Berger M, Frenck W, Chantelau E. Effect of insulin concentration, subcutaneous fat thickness and skin temperature on subcutaneous insulin absorption in healthy subjects.  Diabetologia. 1994;  37 377-380
• 20 Slyper A H. Childhood obesity, adipose tissue distribution, and the pediatric practitioner.  Pediatrics. 1998;  102 e4
• 21 Stern S E, Williams K, Ferrannini E, DeFronzo R A, Bogardus C, Stern M P. Identification of individuals with insulin resistance using routine clinical measurements.  Diabetes. 2005;  54 333-339
• 22 ter Braak E W, Woodworth J R, Bianchi R, Cerimele B, Erkelens D W, Thijssen J H, Kurtz D. Injection site effects on the pharmacokinetics and glucodynamics of insulin lispro and regular insulin.  Diabetes Care. 1996;  19 1437-1440
• 23 Thomas E L, Saeed N, Hajnal J V, Brynes A, Goldstone A P, Frost G, Bell J D. Magnetic resonance imaging of total body fat.  J Appl Physiol. 1998;  85 1778-1785
• 24 UK Prospective Diabetes Study (UKPDS) Group . Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33).  Lancet. 1998;  352 837-853
• 25 Vora J P, Burch A, Peters J R, Owens D R. Absorption of radiolabelled soluble insulin in Type 1 (insulin-dependent) diabetes: influence of subcutaneous blood flow and anthropometry.  Diabet Med. 1993;  10 736-743
• 26 von Mach M A, Brinkmann C, Hansen T, Weilemann L S, Beyer J. Differences in pharmacokinetics and pharmacodynamics of insulin lispro and aspart in healthy volunteers.  Exp Clin Endocrinol Diabetes. 2002;  110 416-419
• 27 Zinman B. The physiological replacement of insulin: an elusive goal.  N Engl J Med. 1989;  321 363-370

1 Preliminary data by [Heise et al. (2005)] employing a BIOSTATOR supported clamp technique are affirmative.